Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

Navneet Education - Q4FY22 Result Update - Growth levers in place - BUY

Posted On: 2022-06-24 13:06:48 (Time Zone: IST)

Mr. Jinesh Joshi - Research Analyst at Prabhudas Lilladher Pvt. Ltd.

Quick Pointers:

- Publication and stationary revenue to breach pre-COVID base in FY23E.

- Stationary exports to grow at 25% CAGR over 3-4 years.

While NELI's top-line was ahead of our estimates due to swift recovery in stationary exports; GM at 53.8% was broadly in-line with our expectation. Though syllabus change schedule for FY23E is not exciting (see exhibit 6); given last academic cycle was impacted by COVID usage of 2nd hand books can be lower aiding growth in publishing segment. On the other hand, management commentary on stationary exports continues to remain bullish and top-line CAGR of 25% is envisaged over next 3-4 years. Apart from strong tailwinds in publishing & stationary exports, NELI has intensified focus on Ed-Tech. Besides ear-marking Rs600mn towards spends in Navneet Future Tech, additional investment of Rs375mn will be made in SFA, a sports tech company in FY23E. While we cut our EPS estimates by 15%/6% for FY23E/FY24E to account for increased spends in Ed-Tech we maintain our BUY rating on the stock with a TP of Rs121 (12x FY24E EPS; no change) amid 1) expected normalcy in publishing business as schools have re-opened 2) strong growth momentum in exports and 3) increasing focus on Ed-Tech.

Standalone sales increase 45.7% YoY: Standalone revenues increased 45.7% YoY to Rs2,779mn (PLe of Rs2,384mn). Publishing sales declined marginally by 1.5% YoY to Rs893mn while stationery sales increased 88.5% YoY to Rs1,878mn. Within the stationery division, exports contributed 49% of sales.

Gross/EBITDA margins at 53.8%/14.6%: Gross profit increased 34.5% YoY to Rs1,494mn with a margin of 53.8% (PLe of 53.0%). Standalone EBITDA increased 36.3% YoY to Rs406mn (PLe of Rs360mn) with a margin of 14.6% (PLe of 15.1%) as compared to margin of 15.6%/15.3% in 4QFY21/3QFY22 respectively. Publishing and stationery EBIT margin was 18.7% and 14.4%.

Con-call highlights: 1) Stationery exports to grow at 25% CAGR over 3-4 years. 2) Stationery export margins to be maintained at pre-pandemic levels of ~16% in FY23E. Since export orders are taken in advance it is difficult to pass on the paper price hike but Rupee depreciation will act as a cushion.4) Stationery and publishing revenue expected to breach pre-pandemic levels in FY23E. 5) Capex of Rs1bn is planned for stationery business over 5 years. ~Rs400mn to be spent in FY23E & FY24E. 6) Indiannica to grow at ~15% CAGR over few years. 7) Indiannica reported highest ever EBITDA of Rs20mn and is expected to be PAT positive in FY23E. 8) Navneet Future Tech has invested ~Rs300mn in 3 companies in FY22. 9) Investment of Rs600mn/Rs375mn planned towards Navneet Future Tech/SFA in FY23E. 10) As per latest valuation round Navneet's share (27% stake) in K12 is valued at Rs6bn. 11) K12 reported revenue/EBITDA loss of Rs1650mn/Rs20mn respectively in FY22. 12) No plans to monetize investment in K12 as of now.

Shares of Navneet Education Limited was last trading in BSE at Rs. 86.95 as compared to the previous close of Rs. 87.55. The total number of shares traded during the day was 9983 in over 281 trades.

The stock hit an intraday high of Rs. 88.85 and intraday low of 82.00. The net turnover during the day was Rs. 857957.00.

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

Gladiator Stocks - Minda Industries - ICICI Direct

Reliance Industries - Company Update - In fine fettle amidst global uncertainty - BUY

Sector Update - Sugar - ICICI Direct

Initiating Coverage - Hindustan Aeronautics Ltd - ICICI Direct

Rallis India - Company Update - Margin pressure likely to persist in near term..!! - Upgrade to 'BUY'

Indoco Remedies - Q4FY22 Result Update - In-line quarter; strong revenue guidance for US & EU mkt - Upgrade to 'BUY'

Indraprastha Gas - Q4FY22 Result Update - Impressive performance - BUY

KEC International - Annual Report Analysis - Healthy outlook across business segment - Accumulate

Westlife Development - Q4FY22 Result Update - Approaching the tipping point; Buy for LT Gains

Reliance Research downgrades Bajaj Auto to Sell

NOCIL - Q4FY22 Result Update - Strong operating performance amidst challenges - BUY

Gujarat Gas - Company Update - Deftly negotiating through tough times - BUY

Orient Electric - Gaining market share via innovation: initiate with ADD - ICICI Securities

Manappuram Finance - Q4FY22 Result Update - Intense Competition Put Pressure on Yields - BUY

Derivatives Weekly View - June 24, 2022 - ICICI Direct

Stock Tales - Newgen Software - ICICI Direct

Weekly Report - June 25, 2022 - Mr. Mitul Shah - Head of Research at Reliance securities

Gladiator Stocks - Bosch - ICICI Direct

Management Meet Update - Sheela Foam - ICICI Direct

Gladiator Stocks - Mahindra & Mahindra - ICICI Direct

Banks - Modifications to PPI and its impact on cards - Negligible impact, if any, for stocks under coverage

LIC Housing Finance - Q4FY22 Result Update - Fixed rate liabilities could cushion NIM - BUY

MPC Minutes: Jun-22: All eyes on inflation - Acuité Ratings

Nazara Technologies - Management Meet Update - Breaking through the ESports landscape - BUY

Sector update - Quick Service Restaurants - YES Securities

JK Lakshmi Cement - Q4FY22 Result Update - Strong performance; Valuations drive upgrade - Accumulate

Would it be wise to invest in a home early in your career?

Dr. Reddy's Laboratories - Analyst Meet Update - Multiple growth initiatives - BUY

Dhanuka Agritech - Management Meet Update - 1Q likely to be subdued; all hopes pinned on the monsoons - BUY

BUY Ipca Laboratories - Q4FY22 Result Update - Weak exports; gradual recovery

Acuité expects India's current account deficit to widen to more than USD 90 bn in FY23 - Acuité Macro Pulse

Inflationary concerns will continue to weigh on the pace of economic revival in FY23 - Acuité Macroeconomic Performance index

City Union Bank - Q4FY22 Result Update - Asset quality on the mend - BUY

Banks - BNPL - Early results are not that exciting as yet - Kotak

Acuité expects FY23 GDP growth estimate at 7.5% - Acuité Macro Pulse - Growth - May-22 Edition

Base factor pushes up IIP in Apr-22 to an 8-month high - Acuité Ratings

India Strategy & Q4FY22 Review - Long term growth prospects to overshadow near term uncertainties

India Equity Strategy - Quarterly flipbook: Q4FY22-Cost inflation driving downgrades

FMCG - D2C is here to stay; omni-channel the way forward - HDFC Securities

Automobile Sector - Monthly Quick View - May'22 - Steady Performance Improvement, backed by Gradual Rural Recovery

BFSI - New normal rate cycle; brace for transmission effects - HDFC Securities

SBI Cards and Payment Services - BUY - TP Rs. 1260 - YES SECURITIES

RBI frontloads rate hike amid increased inflationary headwinds - Acuité Ratings

Monetary Policy June 2022 - Axis MF Views

RBI Monetary Policy View - Mr. Dhiraj Relli, MD & CEO, HDFC Securities

Monetary Policy - entering the red zone - Anuj Puri, ANAROCK

Mr. Murali Ramakrishnan, MD &CEO, South Indian Bank on RBI Monetary Policy

Comments on RBI's MPC Policy Jun'22 - Acuité Ratings

Views on RBI Monetary Policy - June 2022

Bayer Cropscience - Q4FY22 Result Update - Healthy all round performance - BUY

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020